FDA Approves Tenapanor for Treatment of Chronic Kidney Disease
The FDA has approved tenapanor (Xphozah; Ardelyx, Inc.), making it the first and only phosphate absorption inhibitor approved to reduce serum phosphorus in adults with chronic kidney disease (CKD) who are on dialysis as adjunctive therapy in patients who either do not respond to phosphate binders or who are intolerant to any dose of phosphate …